{"name": "Amarantus BioSciences",
 "permalink": "amarantus-biosciences",
 "crunchbase_url": "http://www.crunchbase.com/company/amarantus-biosciences",
 "homepage_url": "http://www.amarantus.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "(408) 737-2734 ",
 "description": "",
 "created_at": "Wed Jun 01 02:14:14 UTC 2011",
 "updated_at": "Wed Jun 01 02:14:35 UTC 2011",
 "overview": "\u003Cp\u003EAmarantus BioSciences is a development-stage, publicly-traded biotechnology company discovering \u0026amp; developing first-in-class treatments for diseases associated with the dysfunction of a wide range of biological pathways, beginning with apoptosis.\u003C/p\u003E\n\n\u003Cp\u003ENeurodegenerative diseases such as Parkinson\u00e2\u20ac\u2122s, ALS and Alzheimer\u00e2\u20ac\u2122s as well as Cardiovascular Disease such as Myocardial Infarction, Angina, Coronary Artery Disease and Heart Failure are in dire need of treatments that address the region specific apoptosis associated with each disorder.\u003C/p\u003E\n\n\u003Cp\u003EAmarantus BioSciences intends to advance therapies that will provide patients with safe and effective treatment options and help curb the soaring healthcare costs associated with care of chronic illnesses. The Company is currently focusing on the development of its lead drug candidate AMRS001 for Parkinson\u00e2\u20ac\u2122s Disease and Cardiac Ischemia. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       39],
      "assets/images/resized/0013/7254/137254v1-max-150x150.png"],
     [[250,
       65],
      "assets/images/resized/0013/7254/137254v1-max-250x250.png"],
     [[255,
       67],
      "assets/images/resized/0013/7254/137254v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO, Chairman",
    "person":
     {"first_name": "Martin",
      "last_name": "D. Cleary",
      "permalink": "martin-d-cleary",
      "image": null}},
   {"is_past": false,
    "title": "COO",
    "person":
     {"first_name": "Gerald",
      "last_name": "E. Commissiong",
      "permalink": "gerald-e-commissiong",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Marc",
      "last_name": "E. Faerber",
      "permalink": "marc-e-faerber",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "c/o The Parkinson\u00e2\u20ac\u2122s Institute ",
    "address2": "675 Almanor Ave. ",
    "zip_code": "94085",
    "city": "Sunnyvale",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "Amarantus licenses Generex's RapidMist for $10M",
    "stoned_year": 2011,
    "stoned_month": 5,
    "stoned_day": 31,
    "source_url": "http://www.masshightech.com/stories/2011/05/30/daily10-Amarantus-licenses-Generexs-RapidMist-for-10M.html",
    "source_text": "",
    "source_description": "Amarantus licenses Generex's RapidMist for $10M",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "Amarantus BioSciences",
      "permalink": "amarantus-biosciences"}}],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}